Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia

被引：7

作者：

Oztas, P

Erbasi, S

Lenk, N

Polat, M

Han, O

Artuz, F

Alli, N

机构：

[1] Ankara Numune Educ & Res Hosp, Dermatol Clin 1, TR-06520 Cukurambar Ankara, Turkey

[2] Ankara Numune Educ & Res Hosp, Hematol Clin, TR-06520 Cukurambar Ankara, Turkey

[3] Ankara Numune Educ & Res Hosp, Pathol Clin, TR-06520 Cukurambar Ankara, Turkey

来源：

ACTA DERMATO-VENEREOLOGICA | 2006年 / 86卷 / 02期

关键词：

D O I：

10.2340/00015555-0015

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：174 / 175

页数：2

共 8 条

[1] An overview of targeted treatments in cancer [J].

Abou-Jawde, R ;

Choueiri, T ;

Alemany, C ;

Mekhail, T .

CLINICAL THERAPEUTICS, 2003, 25 (08) :2121-2137

[2] Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia [J].

Breccia, M ;

Latagliata, R ;

Carmosino, I ;

Mandelli, F ;

Alimena, G .

LEUKEMIA, 2004, 18 (01) :182-182

[3] Severe periorbital edema secondary to STI571 (Gleevec) [J].

Esmaeli, B ;

Prieto, VG ;

Butler, CE ;

Kim, SK ;

Ahmadi, MA ;

Kantarjian, HM ;

Talpaz, M .

CANCER, 2002, 95 (04) :881-887

[4] Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis [J].

Hasselbalch, HC ;

Bjerrum, OW ;

Jensen, BA ;

Clausen, NT ;

Hansen, PB ;

Birgens, H ;

Therkildsen, MH ;

Ralfkiær, E .

AMERICAN JOURNAL OF HEMATOLOGY, 2003, 74 (04) :238-242

[5]

Melo Junia V, 2003, Hematology Am Soc Hematol Educ Program, P132

[6] A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].

NARANJO, CA ;

BUSTO, U ;

SELLERS, EM ;

SANDOR, P ;

RUIZ, I ;

ROBERTS, EA ;

JANECEK, E ;

DOMECQ, C ;

GREENBLATT, DJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245

[7] Imatinib mesylate causes hypopigmentation in the skin [J].

Tsao, AS ;

Kantarjian, H ;

Cortes, J ;

O'Brien, S ;

Talpaz, M .

CANCER, 2003, 98 (11) :2483-2487

[8]

Turkina AG, 2003, TERAPEVT ARKH, V75, P62

← 1 →